Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Calidi Biotherapeutics, Inc. (CLDI) had Return on Tangible Equity of -107.98% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-4.06M |
|
-- |
|
-- |
|
$4.47M |
|
$-4.47M |
|
$0.41M |
|
$-4.06M |
|
$-4.30M |
|
$-4.06M |
|
$-4.06M |
|
$-4.06M |
|
$-4.30M |
|
$-4.47M |
|
$-4.04M |
|
4.30M |
|
4.30M |
|
$0.41 |
|
$0.41 |
|
| Balance Sheet Financials | |
$6.26M |
|
$0.78M |
|
$2.60M |
|
$8.86M |
|
$3.94M |
|
$0.77M |
|
$1.16M |
|
$5.10M |
|
$3.76M |
|
$3.76M |
|
$3.76M |
|
7.22M |
|
| Cash Flow Statement Financials | |
$-21.29M |
|
$-0.17M |
|
$17.46M |
|
$9.81M |
|
$5.82M |
|
$-3.99M |
|
$2.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.59 |
|
-- |
|
-- |
|
0.17 |
|
0.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-21.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-107.98% |
|
|
Return on Tangible Equity |
-107.98% |
-45.83% |
|
-89.60% |
|
$0.52 |
|
$-4.98 |
|
$-4.95 |
|